Biopharma companies at AMP 2026
Nov 10–14, 2026 Seattle, WA ~2k attendees Website
10 biopharma companies are at AMP 2026 — 3 presentations on the program and 8 with a booth in the exhibit hall. 9 of them have their own page in this guide. As of Sep 25, 2026.
Program track
Top represented
Showing 1–10 of 10 organizations
| Organization | AMP 2026 Attendance |
|---|---|
Eli Lilly Indianapolis, IN | |
Pharmaceutical company discovering, developing and marketing medicines, and running clinical trials worldwide. | Booth Exhibiting at Booth 831, MR5 Thu, Nov 1211:15am–7:00pmFri, Nov 139:00am–4:00pmSat, Nov 149:00am–1:30pm |
Merck & Co. Rahway, NJ | |
Pharmaceutical company developing oncology medicines, with a large clinical research program in cancer. | Booth Exhibiting at Booth 801, MR9 Thu, Nov 1211:15am–7:00pmFri, Nov 139:00am–4:00pmSat, Nov 149:00am–1:30pm 🏅Gold Partner |
AbbVie North Chicago, IL | |
Pharmaceutical company developing medicines across immunology, oncology, neuroscience, eye care and aesthetics. | Booth Exhibiting at Booth 908 Thu, Nov 1211:15am–7:00pmFri, Nov 139:00am–4:00pmSat, Nov 149:00am–1:30pm 🏅Gold Partner |
Amgen Thousand Oaks, CA | |
Independent biotechnology company developing and marketing medicines for serious illnesses. | Booth Exhibiting at Booth 1703 Thu, Nov 1211:15am–7:00pmFri, Nov 139:00am–4:00pmSat, Nov 149:00am–1:30pm 🏅Gold Partner |
AstraZeneca Cambridge, UK | |
Biopharmaceutical company developing prescription medicines in oncology; cardiovascular, renal and metabolism; and respiratory disease. | Booth Exhibiting at Booth 820 Thu, Nov 1211:15am–7:00pmFri, Nov 139:00am–4:00pmSat, Nov 149:00am–1:30pm 🏅Diamond Partner |
Johnson & Johnson New Brunswick, NJ | |
Johnson & Johnson Innovative Medicine develops medicines in oncology, immunology, neuroscience, cardiovascular disease, pulmonary hypertension and retina. | Booth Exhibiting at Booth 817 Thu, Nov 1211:15am–7:00pmFri, Nov 139:00am–4:00pmSat, Nov 149:00am–1:30pm 🏅Platinum Partner Workshop Wed, Nov 11 8:00am–8:50am The Precision Pathway: How Pathologists Are Transforming Biomarker Discovery, Selection, and Clinical Impact Across GU Cancers Biomarker selection, specimen handling and reporting for genitourinary cancers, worked through interactive case discussions. |
Pfizer New York, NY | |
Pharmaceutical company; its oncology unit develops medicines for some of the world's most common cancers. | Booth Exhibiting at Booth 1023 Thu, Nov 1211:15am–7:00pmFri, Nov 139:00am–4:00pmSat, Nov 149:00am–1:30pm 🏅Gold Partner |
Revolution Medicines Redwood City, CA | |
Oncology company developing oral RAS(ON) inhibitors for patients with RAS-addicted cancers. | Booth Exhibiting at Booth 528 Thu, Nov 1211:15am–7:00pmFri, Nov 139:00am–4:00pmSat, Nov 149:00am–1:30pm Workshop Wed, Nov 11 3:00pm–3:50pm RAS in ACTION - From A Single Mutation to a Targeted Class RAS mutation testing across lung, colorectal and pancreatic cancers, with tissue and liquid biopsy considerations for targeted therapy. Workshop Thu, Nov 12 4:25pm–4:55pm It's Hard to Treat What You Can't See: Leveraging Molecular Diagnostics to Improve Care of Patients with Pancreatic Lesions Pancreatic lesions are hard to call on imaging and cytology alone; molecular testing can sharpen diagnosis and risk stratification. |
Pharmaceutical company developing medicines in oncology, hematology, immunology and cardiovascular disease. | 🏅Gold Partner |
Eli Lilly's oncology research and development unit, developing targeted cancer medicines. | 🏅Gold Partner |
Instantly find 20 buyers from biopharma companies
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse AMP 2026 by
Organization type
Program track
Exhibit hall
Everyone
Not affiliated with the Association for Molecular Pathology. Organization details are derived from AMP’s published lists. Submit a correction